Reports Q3 revenue $133.5M, consensus $122.6M. “Our record third quarter results reflect continued strong momentum in our business driven by successful global execution of our key strategic plans,” said Thomas Burns, CEO. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos Corp. Advances NEXAGON® Study for Eye Condition Treatment
- Glaukos Corp. Advances in Glaucoma Treatment with New Clinical Trial
- Glaukos Corp.’s iDose TR Study: A Potential Game-Changer in Ophthalmic Treatment
- Microsoft upgraded, Harley-Davidson downgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades Glaukos on ‘underappreciated’ growth opportunity